ORYZON to hold multiple corporate activities in January

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will update on corporate progress at several renowned international events in January.

Oryzon will participate at the LifeSci Advisors Annual Corporate Access Event, to be held virtually on January 5-7. During this event Dr. Carlos Buesa, Oryzon’s CEO, will participate in a panel of five European Companies entitled "The Best of Both Worlds: Defining Yourself When You Fit Into More Than One Basket" on January 7 at 10:00 am ET.  https://www.meetmax.com/sched/event_78427/invitee_login.html

Oryzon has been invited to participate at the 40th Annual J.P. Morgan Healthcare Conference, to be held virtually on January 10-13. https://www.jpmorgan.com/solutions/cib/insights/health-care-conference

In parallel, the company will attend the digital Biotech Showcase 2022 on January 10-12, where it will hold one-to-one meetings with pharmaceutical companies and global investors and will present a corporate update, which will be available on-demand to all registered attendees. https://informaconnect.com/biotech-showcase/

The company will also participate at the H.C.Wainwright Bioconnect Conference, to be held virtually on January 10-13 presenting a corporate update, which will be available to conference attendees from January 10 at 07:00 am ET (On-Demand Session). https://hcwevents.com/bioconnect/

Oryzon will also attend the BioMed Event 2022, which will be held on January 26 in Paris, France. http://biomedtechevent.com/

More info about the company and contact in the file attached.